Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

8.940 -0.310 (-3.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023 ↗
 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Analyst Expectations for Day One Biopharmaceutical's Future ↗
 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lam Research, D.R. Horton, Las Vegas Sands And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Where Day One Biopharmaceutical Stands With Analysts ↗
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Cowen 43rd Annual Health Care Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This Pediatric Cancer Company Makes It To Analyst's Conviction List ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗
 
Via Benzinga
News headline image
Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses ↗
 
Via Benzinga
News headline image
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗
 
Via Benzinga
News headline image
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.